Allergan near buyout deal of up to US$65b to escape Valeant, Ackman: source
Actavis may pay Botox maker between US$215 and US$220 per share
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
ALLERGAN Inc is close to a buyout deal worth up to US$65.5 billion by Actavis plc, one that could end months of pursuit by Canada's Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.
Actavis may pay Allergan between US$215 and US$220 per share, with the final price likely coming at the high end of that range, according to the source. A deal could be announced as early as Monday, the source added.
Share with us your feedback on BT's products and services
TRENDING NOW
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
